Trends and causes of etiology in adult liver transplant patients: multicenter study

measure using flow cytometry; qRT-PCR and ELISA (Human DuoSet ELISA, DY210/DY285B, RandD systems).Results: In hepatocytes, different dosage of Andro (5, 10, 25 μM) caused no toxicity.High dosage of Andro (25 μM) reduced the level of free/total cholesterol ( p <0.01) (Figure 1A), decreased amount of lipid droplets (Figure 1B), and increased the mitochondrial DNA copy numbers, mRNA expression of PGC-1α, GCLC, GCLM, HO-1 and NQO1 ( p <0.05) (Figure 1C).Furthermore, Andro (5, 10, 25 μM) decrease the percentage of TNF-α, IFN-γ or IL-17-producing T cells and reduced mRNA expression of TNF-α and IFN-γ in T cells ( p <0.05, P < 0.01, P < 0.0001).Andro (25 μM) also decreased the protein level of TNF-α and IFN-γ in T cell culture supernatant ( p <0.01) (Figure 1D).Conclusion: Andro is effective in reducing lipid content, promoting mitochondrial biogenesis and activating anti-oxidative system in hepatocytes.In addition, Andro inhibited Th1 and Th17 immunity.These results show that Andro has a great potential to rescue those marginal liver grafts to ease graft shortage in the setting of human liver transplantation.